Earlier this week, San Diego Gallland announced $ 18 million funding to bring the first treatment with ready -made stem cell approved by FDA in veterinary medicine. If a regulatory concentration passes, it could create a completely new way of dealing with our babies.
It is still an experimental field, even though people have researched stem cells for people for decades. The first goal of the seven -year -old Gallant is a painful condition in the mouth in cats called chronic Ulosomatitis (FCGS), which Gallant says he could obtain approval from the beginning of FDA 2026.
The field has shown some encouraging early results. Study arthritis dogs They have shown improvements in pain and mobility, with some benefits that last for up to two years. But when the researchers tried similar renal disease treatments in cats – this is another condition that wants to deal with – the results were mixed.
What makes Gallant’s approach is different is convenience. Most stem cell treatments currently require the patient or donors with the corresponding tissue, while the treatment of Gallant uses ready -to -use donor cells, even if it is a different kinds.
Investors clearly see the opportunities here. The funding tour was driven by the existing Backer Digitalis Ventures, with the participation of Novaquest Capital Management, which was previously invested in the first treatment with human stem cells approved by the FDA.
The company has an interesting backstory. The founder of Gallant, Aaron Hirschhorn, previously sell Dogvacay in his biggest opponent in the dog market, Rover. Peninsan died 2021? Gallant is now driven by Linda Black, who joined as president and chief scientific official from almost the beginning. Gallant has now raised at least $ 44 million from investors.
